RxDoctor Payments Data

Miata Wallace, PA

Physician Assistant · Lincoln, NENPI 1013656990

Payments from drug & device makers

$1,824in general payments, 2019–2025

Across 77 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avadel CNS Pharmaceuticals, LLC$251
  • Jazz Pharmaceuticals Inc.$224
  • Grifols USA, LLC$207
  • Harmony Biosciences LLC$137
  • Astellas Pharma US Inc$115
  • United Therapeutics Corporation$113
  • plus $776 from 17 others

What the payments were for

  • Consulting fees$20011%
  • Food & beverage$1,45980%
  • Education$1659%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,824 in reported general payments places this provider in the 80th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$16,077
Medicare patients
155
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter167$118,187
Dupixent PenDupilumab27$117,963
NucalaMepolizumab16$68,497
Stiolto RespimatTiotropium Br/Olodaterol Hcl63$39,038
YupelriRevefenacin22$31,918
Breo ElliptaFluticasone/Vilanterol71$30,946
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr57$27,909
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$27,694
Spiriva RespimatTiotropium Bromide24$17,961
SymbicortBudesonide/Formoterol Fumarate62$16,496
DuleraMometasone/Formoterol42$15,494
Bevespi AerosphereGlycopyrrolate/Formoterol Fum31$13,299
Formoterol Fumarate11$10,118
Advair HfaFluticasone Propion/Salmeterol23$9,101
Incruse ElliptaUmeclidinium Bromide19$7,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$32$255,150341 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$75$57,488134 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$108$56,99987 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →